Bristol-Myers Squibb | BMY - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 14.8B 411M 2026-09
Abbott USD 7.45B 799M 2026-09
ALKERMES USD 375.31M 43.98M 2026-06
Amgen USD 5.87B 1.02B 2026-03
AstraZeneca USD 13.28B 421M 2026-09
Biogen USD 2.25B 127.8M 2026-09
Bristol-Myers Squibb USD 9.26B 1.19B 2026-06
Coherus Biosciences USD 8.7M 853K 2025-12
Drreddys Laboratories INR 45.2B 2.17B 2026-09
Eli Lilly USD 20.59B 886M 2026-09
Gilead Sciences USD 6.73B 74M 2026-09
GlaxoSmithKline GBP 6.51B 757M 2026-06
J&J USD 18.55B 6M 2026-09
Medtronic USD 6.36B 355M 2026-06
Merck USD 12.21B 121M 2026-06
Novartis USD 11.42B 180M 2026-09
Novo Nordisk DKK 64.01B 1.19B 2025-06
Perrigo USD 313.9M 11.6M 2026-06
Pfizer USD -248M 11.29B 2026-06
Phibro Animal Health USD 133.5M 12.6M 2025-12
Prestige Brands USD 136.19M 10.11M 2026-06
Regeneron Pharmaceuticals USD 3.71B 778.2M 2026-06
Roche Holding CHF 22.69B 600M 2026-06
Sanofi EUR 11.7B 2.99B 2026-09
Sanofi EUR 9.28B 1.18B 2026-06
United Therapeutics USD 683.8M 35.7M 2026-06
Zoetis USD 1.76B 140M 2026-06